Back to Search
Start Over
[Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
- Source :
-
Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Apr; Vol. 32 (2), pp. 643-646. - Publication Year :
- 2024
-
Abstract
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a relatively inert B lymphocyte proliferative disease. In recent years with the launch of new drugs, chemotherapy has been gradually replaced by targeted therapy, which significantly prolongs the survival of patients and reduces the side effects of treatment. At present, BTK inhibitors, PI3K inhibitors, spleen tyrosine kinase (SYK) inhibitors and BCL-2 inhibitors are the most studied targeted therapeutic drugs for CLL/SLL. This article reviews the research progress of different types of targeted therapeutic drugs in the treatment of CLL/SLL.
- Subjects :
- Humans
Molecular Targeted Therapy
Syk Kinase antagonists & inhibitors
Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors
Proto-Oncogene Proteins c-bcl-2
Protein Kinase Inhibitors therapeutic use
Antineoplastic Agents therapeutic use
Phosphoinositide-3 Kinase Inhibitors
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Subjects
Details
- Language :
- Chinese
- ISSN :
- 1009-2137
- Volume :
- 32
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Zhongguo shi yan xue ye xue za zhi
- Publication Type :
- Academic Journal
- Accession number :
- 38660880
- Full Text :
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.02.049